Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human ALCAM Protein, His tag, 200 µg  

Recombinant Human ALCAM Protein, His tag, 200 µg

Recombinant Human ALCAM Protein (Trp 28 - Ala 526), produced in human 293 cells (HEK293), His tag

Synonym
Recombinant Human protein, CD166,ALCAM,CD6L,KG-CAM,MEMD

More details

CD6-H5228-200

Availability: within 7 days

325,00 €

Background
CD166 antigen is a 100-105 kD typeI transmembrane glycoprotein that is a member of the immunoglobulin superfamily of proteins, which is also known as Activated leukocyte cell adhesion molecule (ALCAM) in human, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat. CD166 is a cell adhesion molecule that binds to CD6. CD166 involved in neurite extension by neurons via heterophilic and homophilic interactions.

Source
Recombinant Human ALCAM, His Tag (CD6-H5228) is expressed from human 293 cells (HEK293). It contains AA Trp 28 - Ala 526 (Accession # Q13740-1).
Predicted N-terminus: Trp 28

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 57.8 kDa. The protein migrates as 70-100 kDa under reducing (R) condition, and 66-100 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Polymorphisms in the CD6-ALCAM axis may modulate psoriasis risk and outcomes"
Wagner, Sobczyński, Wiśniewski et al
Hum Immunol (2024)
(2) "Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects"
Hu, Wang, Wang et al
Oncol Res (2024) 32 (4), 753-768
(3) "Molecular Determinants Involved in the Docking and Uptake of Tumor-Derived Extracellular Vesicles: Implications in Cancer"
Clares-Pedrero, Rocha-Mulero, Palma-Cobo et al
Int J Mol Sci (2024) 25 (6)
Showing 1-3 of 836 papers.